What people are saying.
Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC)
Hubble Contacts Closes Series A-III Financing to Support Global Growth
Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cell Design Labs Appoints Roger Sidhu, M.D. As Chief Medical Officer